TLC-2716

TLC-2716 is a potent, oral, small-molecule, liver-targeted inverse agonist of the Liver X Receptor (LXR), specifically inhibiting both LXRα and LXRβ. It modulates plasma triglycerides and cholesterol by multiple mechanisms, including inhibition of de novo lipogenesis, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption. The drug is being developed primarily for severe hypertriglyceridemia (SHTG) and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH). Preclinical models have shown that TLC-2716 leads to significant reductions in hepatic and plasma triglycerides as well as plasma cholesterol. The compound was originally discovered by Phenex Pharmaceuticals and is currently being developed by OrsoBio[1][2][3][5][6].